Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1. Raffi, F.
2. Rachlis, A.
3. Stellbrink, H.-J.
4. Hardy, W.D.
5. Torti, C.
6. Orkin, C.
7. Bloch, M.
8. Podzamczer, D.
9. Pokrovsky, V.
10. Pulido, F.
11. Almond, S.
12. Margolis, D.
13. Brennan, C.
14. Min, S.